The Low Carb Diabetic

Promoting a low carb high fat lifestyle for the safe control of diabetes. Eat whole fresh food, more drugs are not the answer.


Welcome to the Low Carb Diabetic forum,have you signed up yet? if not then sign up and join us in the low carb community today!

    Canagliflozin, Dapagliflozin Warnings Strengthened by FDA

    Share
    avatar
    graham64
    Member

    Status :
    Online
    Offline

    Male Posts : 2728
    Join date : 2014-08-10
    Location : Lancs

    Canagliflozin, Dapagliflozin Warnings Strengthened by FDA

    Post by graham64 on Wed Jun 15 2016, 21:40

    The US Food and Drug Administration (FDA) has strengthened its drug label warnings about the risk for acute kidney injury that can result from the use of the type 2 diabetes prescription medications canagliflozin (Invokana, Invokamet, Janssen) and dapagliflozin (Farxiga, Xigduo XR, AstraZeneca), according to an agency news release.

    The revised warnings include information about acute kidney injury and recommendations for minimizing this risk.

    The medications are sodium-glucose cotransporter-2 (SGLT2) inhibitors and are used with diet and exercise to lower blood sugar in adults with type 2 diabetes; they exert their effects via glycosuria, whereby the kidneys excrete glucose.

    The FDA approved canagliflozin in March 2013. From that time until October 2015, 101 confirmable cases of acute kidney injury were reported to the FDA in patients who used canagliflozin or dapagliflozin. Dapagliflozin was approved in January 2014.

    In these cases, approximately half of the patients experienced acute renal injury within 1 month of beginning the medication, and some were younger than 65 years. Most improved after discontinuing the drug.

    Some of the affected patients were dehydrated, had low blood pressure, or were taking other drugs that can affect the kidneys.

    Some of these patients required hospitalization and dialysis. The FDA believes there are additional cases that have not been reported.

    There is no mention of any warning with another SGLT2 inhibitor, empagliflozin (Jardiance, Boehringer Ingelheim) in this FDA communication. Ironically, new data from the EMPA-REG OUTCOME trial with this agent just reported today at the American Diabetes Association 2016 Scientific Sessions being held in New Orleans show it significantly reduces the progression to renal disease in the population of type 2 diabetes patients studied, those at high cardiovascular risk.

    Recommendations for Healthcare Professionals


    The FDA advises healthcare professionals to consider factors that may predispose patients to acute kidney injury before starting them on either of the medications. These factors include decreased blood volume; chronic renal insufficiency; congestive heart failure; and taking medications such as diuretics, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs.

    Clinicians should assess the patient's kidney function before beginning canagliflozin or dapagliflozin and monitor it periodically after the patient begins either medication.

    Clinicians should discontinue the medication promptly and treat the renal impairment if acute kidney injury occurs.

    SGLT2 inhibitors have also been associated rarely with fractures ­and diabetic ketoacidosis, and the FDA strengthened the warning with regard to fracture and canagliflozin specifically last September.

    Recommendations for Patients


    Patients who experience signs and symptoms of acute kidney injury should seek immediate medical attention, says the FDA. These can include decreased urination or swelling in the legs or feet.

    The FDA warns that acute renal injury is a serious condition in which the kidneys abruptly stop working and dangerous levels of waste can accumulate in the body.

    The warnings instruct patients not to discontinue their medication without first talking to their healthcare providers because uncontrolled blood glucose levels can develop.

    Patients are instructed to read the medication guide that comes with their canagliflozin or dapagliflozin prescriptions.

    Healthcare professionals and patients should report adverse events or side effects related to the use of these medications to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

    http://www.medscape.com/viewarticle/864859


    _________________
    I'm a skinny T2 diagnosed 4/4/2008, a high calorie LCHF diet and one metformin a day A1c 6.2 and no complications.

    Proving the LowCarb sceptics wrong for over nine years,

    Not all cherubs are Angels  Wink nor all diabetics Bonkers  Rolling Eyes
    avatar
    yoly
    Member

    Status :
    Online
    Offline

    Posts : 390
    Join date : 2014-08-14

    Re: Canagliflozin, Dapagliflozin Warnings Strengthened by FDA

    Post by yoly on Wed Jun 15 2016, 21:56

    The wonderful drugs that Dr. Fung and Diet Doctor were recommending all based on a very preliminary report of cardiovascular benefit. Very naive of them knowing the flury of research work that appear while there is money to be made, on new patent medications and costly interventions like bariatric surgery All of it which is probably just hype.

    There are only 3 medications I will consider metformin, acarbose because is excreted mainly unprocessed(but is only useful if you eat carbs) and insulin if nothing else work.
    avatar
    chris c
    Member

    Status :
    Online
    Offline

    Posts : 2790
    Join date : 2015-07-26

    Re: Canagliflozin, Dapagliflozin Warnings Strengthened by FDA

    Post by chris c on Wed Jun 15 2016, 22:21

    I agree on the metformin and insulin, don't know enough people who have used acarbose to have an opinion. Don't worry that these drugs fail, there are scads more in the process of being approved. If they also have dangers and even more funky side effects, there'll be some more along later.

    I too was surprised at Eenfeldt and Fung.
    avatar
    graham64
    Member

    Status :
    Online
    Offline

    Male Posts : 2728
    Join date : 2014-08-10
    Location : Lancs

    Re: Canagliflozin, Dapagliflozin Warnings Strengthened by FDA

    Post by graham64 on Wed Jun 15 2016, 22:41

    The market for dubious T2 drugs is huge which is hardly surprising given the dietary advice peddled by DUK, ADA and the BDA etc

    More drug news  Evil or Very Mad

    What's the buzz at ADA? Here's your rundown, with Merck, Pfizer, Sanofi, Novo and more

    http://www.fiercepharma.com/pharma/what-s-buzz-at-ada-here-s-your-rundown-merck-pfizer-sanofi-novo-and-more


    _________________
    I'm a skinny T2 diagnosed 4/4/2008, a high calorie LCHF diet and one metformin a day A1c 6.2 and no complications.

    Proving the LowCarb sceptics wrong for over nine years,

    Not all cherubs are Angels  Wink nor all diabetics Bonkers  Rolling Eyes
    avatar
    chris c
    Member

    Status :
    Online
    Offline

    Posts : 2790
    Join date : 2015-07-26

    Re: Canagliflozin, Dapagliflozin Warnings Strengthened by FDA

    Post by chris c on Wed Jun 15 2016, 23:08

    Can't remember where I read it now but I believe there are over 70 "diabetes drugs" currently in the pipeline.

      Current date/time is Sun May 28 2017, 13:22